Bamlanivimab for the treatment of COVID-19
Austrian Institute for Health Technology Assessment (AIHTA)
Record ID 32018001196
Authors' objectives: The aim of this EUnetHTA Rolling Collaborative Review is to inform health policy at the national/regional and at the European level at an early stage in the life-cycle of therapies which interventions are currently undergoing clinical trials, to monitor (ongoing studies and their results) permanently - in the format of a Living Document - potential therapies against covid-19, to present comparative data on effectiveness and safety of potential therapies and to support preparations for an evidence-based purchasing of regional/ national health politicians, if necessary. To avoid redundancies and duplication, the EUnetHTA Rolling Collaborative Review will reuse sources from international initiatives to collect information and data on Covid-19 treatments.
Project Status: Completed
URL for project: https://eunethta.eu/rcr17/
Year Published: 2021
URL for published report: https://eunethta.eu/rcr17/
Requestor: HTA agencies
English language abstract: An English language summary is available
Publication Type: Rapid Review
- Coronavirus Infections
- Antiviral Agents
- Antibodies, Monoclonal, Humanized
- Drug Therapy
Organisation Name: European Network for Health Technology Assessment
Contact Email: firstname.lastname@example.org
Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.